Abstract | BACKGROUND AND PURPOSE: MATERIALS AND METHODS: Methods To determine the risk factors of PISE, in this study, 78 patients with PISE and 86 patients without PISE were recruited. Clinical data and serum neuropeptide Y (NPY) levels were collected and the relative factors including clinical data and serum were analyzed. RESULTS: Logistic regression showed that low serum NPY was significantly associated with PISE. Every 5 ng/ml increment of serum NPY was associated with 62% risk decrease in patients with PISE. The area under curve of serum NPY was 0.910 with a sensitivity of 84.62% and a specificity of 86.05%. The cut-off value of serum NPY was 90 ng/ml. According to cut-off value of serum NPY, the percentage of patients with PISE decreased from 84.6% in low serum NPY group to 14.0% in high serum NPY group. Furthermore, patients were divided into different tertiles according to serum NPY. The percentage of patients with PISE reduced from 90.0% in the lowest tertile (NPY < 85 ng/ml) to 3.5% in the highest tertile (NPY ≥ 105 ng/ml). Compared with patients with normal video-electroencephalogram (VEEG), serum NPY levels significantly decreased in patients with abnormal VEEG; however, serum NPY levels were not associaated with epileptic seizure subtypes. CONCLUSIONS: Serum NPY was an independent risk factor for PISE. Targeting serum NPY may be used to the prevention and treatment of PISE.
|
Authors | Nuan Wang, Dongxing Wang, Hao Zhou, Cuifu Xu, Xiaowei Hu, Zhiyuan Qian, Xingshun Xu |
Journal | Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
(J Stroke Cerebrovasc Dis)
Vol. 30
Issue 2
Pg. 105475
(Feb 2021)
ISSN: 1532-8511 [Electronic] United States |
PMID | 33242785
(Publication Type: Journal Article)
|
Copyright | Copyright © 2020 Elsevier Inc. All rights reserved. |
Chemical References |
- Biomarkers
- Neuropeptide Y
|
Topics |
- Aged
- Aged, 80 and over
- Biomarkers
(blood)
- Case-Control Studies
- Electroencephalography
- Epilepsy
(diagnosis, etiology)
- Female
- Humans
- Male
- Middle Aged
- Neuropeptide Y
(blood)
- Predictive Value of Tests
- Risk Assessment
- Risk Factors
- Stroke
(blood, complications, diagnosis)
|